Childhood, adolescent and young adult cancer survivors treated with head or brain radiotherapy or cisplatin have an increased risk of hearing problems. Because of this high risk survivors may benefit from surveillance for hearing loss.
Quality of LifeAllGuidelines
IGHG Ototoxicity Guideline
Recommendations for surveillance for ototoxicity (hearing loss, tinnitus, or both) in survivors who were treated with platinum chemotherapy or radiotherapy to the brain or ear.
Published:
Continue reading · Quality of LifeIGHG Ototoxicity Surveillance RecommendationsRecommendations for surveillance for ototoxicity in survivors who were treated with platinum chemotherapy or radiotherapy to the brain or ear.
Discussion & Questions
Note: Comments are for discussion and clarification only. For medical advice, please consult with a healthcare professional.
Leave a Comment
No comments yet
Be the first to share your thoughts!
Related Resources
IGHG Guideline on Central Nervous System Neoplasms
Recommendations for surveillance for central nervous system neoplasms in survivors who were treated with cranial radioth...
Quality of LifeAll
Read
IGHG Guideline on Coronary Artery Disease Surveillance
Recommendations for surveillance for coronary artery disease in survivors
Quality of LifeAll
Read
IGHG Guideline on Hepatic Toxicity
Recommendations for surveillance for hepatic toxicity in survivors
Quality of LifeAll
Read